Trade & Exports

China's external position is unchanged this round, and so is the standing judgment: a manufactured-goods surplus large enough to make China the default target of foreign trade-remedy action, recycled abroad through the capital account, sits alongside a Chinese remedy toolkit now pointed outward. What is new in this batch is almost entirely diplomatic — summit choreography, a Togo state visit, a France strategic dialogue — not commercial. No document here moves the trade numbers or the policy architecture.

The core figures are the ones already on the record. SAFE's second-quarter balance of payments shows a goods trade surplus of $278.8bn and a current account surplus of $193.7bn; H1 current account reached $378.0bn ¹. August's monthly goods surplus was $116.3bn against a services deficit of only $21.8bn ². Goods carry essentially the whole surplus, which means the pressure point is manufactured volume — precisely the composition that feeds foreign "overcapacity" charges and anti-dumping exposure.

The offset remains the least-read part of the story. The capital and financial account ran a $157.1bn deficit in Q2 and $345.2bn in H1, closely matching the current account ¹. That is net lending to the rest of the world: China runs the surplus and exports the proceeds. The external balance sheet looks sturdier than the headline suggests — end-June full-scale external debt of 170,148bn yuan ($2.498trn) is 59% short-term, but 41% of that short-term stock is trade-related credit and 56% of the total is renminbi-denominated ³.

The sharpest commercial item in this cycle remains China's own anti-dumping case. On 14 September 2026, Jiangsu Huaihe Chemical and Hubei Dongfang Chemical petitioned MOFCOM; on 3 October the ministry opened an investigation into p-nitrotoluene originating in the EU, with a dumping period of 1 July 2025 to 30 June 2026 and an injury period running from 1 January 2022 ⁴. This is a routine, WTO-consistent instrument, but it is also the marker of Beijing as plaintiff rather than defendant — EU chemical exporters now sit in the same queue Chinese exporters occupy abroad. Watch whether it is a one-off or the first of a wave.

The policy architecture on both legs is intact. On exports, MOFCOM's 2027 auto and motorcycle licence regime (Shang Ban Mao Han No. 404) still demands proof of overseas after-sales and repair networks, with false filings risking suspension or revocation ⁵, and the precursor-chemicals catalogue still routes US, Mexican and Canadian buyers through licensing ⁶. On domestic absorption, Jin Fa No. 17 continues to push domestic trade credit insurance (内贸险) and domestic-foreign trade integration ⁷. These are the channels that convert external surplus into home-market demand.

The multilateral stage keeps thickening ahead of November's APEC leaders' meeting in Shenzhen, run as "APEC China Year" with Putin confirmed as a welcomed guest ⁸. Li Qiang opened the 5th Global Digital Trade Expo in Hangzhou, pitching open-source AI and freer digital trade to roughly 1,200 delegates from nearly 50 countries ⁹, and the National Energy Administration met Singapore's trade-and-industry minister on power interconnection ¹⁰. This batch adds only more calendar: a Togo state visit (9–16 October) and a China-France strategic dialogue (9–13 October) ¹¹. These are platforms for the narrative, not market-access deliverables.

Two limits bound this reading. First, the only fresh trade-adjacent signal in the new documents is a press question — reported claims that Trump asked China at the last summit to drop export-control measures against Japan, which the MFA declined to confirm ¹¹. Unverified, treat it as noise until an instrument follows. Second, the composition of the outflow stays unresolved: the H1 2026 Balance of Payments Report is published but its detailed tables are still not populated ¹², so the portfolio-versus-direct-investment split remains open. The test this round is unchanged: whether MOFCOM's remedy filings widen beyond p-nitrotoluene, and whether the EU answers in kind.